Lipocine(LPCN) - 2023 Q4 - Annual Results

Exhibit 99.1 Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 SALT LAKE CITY, March 7, 2024 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders, today announced financial results for the year ended December 31, 2023 and provided a corporate update. Neuroactive Steroids LPCN 1148 ● Lipocine announced positive topline results from a pharmacokinetics ("PK") pilot bridge study of LPCN 1154 (oral brexanolone). Lipo ...